New analyses of Ofev data in patients with chronic fibrosing ILD

6 August 2020

Boehringer Ingelheim has announced new analyses of the Phase III INBUILD trial that studied its blockbuster growth driver Ofev (nintedanib) for the treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.

These analyses were published online in conjunction with the American Thoracic Society (ATS) Virtual conference. The accepted abstracts are available here.

In an analysis of the INBUILD trial, the proportion of patients with 10% or greater declines in lung function were lower in the Ofev group relative to placebo. The analysis was based on changes between baseline and 52 weeks in the rate of decline in forced vital capacity (FVC) >5% and FVC >10% predicted. FVC is an established measurement of lung function and loss of FVC is an indicator of disease progression.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK